DECIBEL CANNABIS CO INC (DB.CA) Stock Fundamental Analysis
Canada - TSX-V:DB - CA2434371001 - Common Stock
0.13 CAD
0 (0%)
Overall DB gets a fundamental rating of 4 out of 10. We evaluated DB against 34 industry peers in the Pharmaceuticals industry. While DB is still in line with the averages on profitability rating, there are concerns on its financial health. DB is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year DB has reported negative net income.
In the past year DB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: DB reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: DB reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.45%, DB belongs to the top of the industry, outperforming 91.18% of the companies in the same industry.
With an excellent Return On Equity value of 17.30%, DB belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.45% | ||
| ROE | 17.3% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)-1.43%
ROE(3y)0.45%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DB's Profit Margin of 11.74% is amongst the best of the industry. DB outperforms 85.29% of its industry peers.
In the last couple of years the Profit Margin of DB has grown nicely.
With a Gross Margin value of 28.07%, DB is not doing good in the industry: 61.76% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of DB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 11.74% | ||
| GM | 28.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y45.46%
PM growth 5YN/A
GM growth 3Y72.19%
GM growth 5Y-2.05%
2. Health
2.1 Basic Checks
DB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DB has been increased compared to 1 year ago.
The number of shares outstanding for DB has been increased compared to 5 years ago.
DB has a better debt/assets ratio than last year.
2.2 Solvency
DB has an Altman-Z score of 1.06. This is a bad value and indicates that DB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DB (1.06) is better than 70.59% of its industry peers.
The Debt to FCF ratio of DB is 34.70, which is on the high side as it means it would take DB, 34.70 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DB (34.70) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.58 indicates that DB is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.58, DB is in line with its industry, outperforming 41.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 34.7 | ||
| Altman-Z | 1.06 |
ROIC/WACCN/A
WACC8.64%
2.3 Liquidity
DB has a Current Ratio of 1.33. This is a normal value and indicates that DB is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.33, DB is not doing good in the industry: 64.71% of the companies in the same industry are doing better.
DB has a Quick Ratio of 1.33. This is a bad value and indicates that DB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.43, DB is doing worse than 76.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 70.00% over the past year.
The Earnings Per Share has been growing by 90.70% on average over the past years. This is a very strong growth
DB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.89%.
DB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 71.51% yearly.
EPS 1Y (TTM)70%
EPS 3Y90.7%
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-12.89%
Revenue growth 3Y20.83%
Revenue growth 5Y71.51%
Sales Q2Q%34.67%
3.2 Future
DB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 77.26% yearly.
Based on estimates for the next years, DB will show a quite strong growth in Revenue. The Revenue will grow by 12.81% on average per year.
EPS Next Y235.97%
EPS Next 2Y124.94%
EPS Next 3Y77.26%
EPS Next 5YN/A
Revenue Next Year28.61%
Revenue Next 2Y24.25%
Revenue Next 3Y20.73%
Revenue Next 5Y12.81%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Forward Earnings ratio of 4.25, the valuation of DB can be described as very cheap.
97.06% of the companies in the same industry are more expensive than DB, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.71. DB is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.25 |
4.2 Price Multiples
DB's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DB is cheaper than 64.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.22 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DB's earnings are expected to grow with 77.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y124.94%
EPS Next 3Y77.26%
5. Dividend
5.1 Amount
DB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:DB (9/16/2025, 7:00:00 PM)
0.13
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners4.97%
Ins Owner ChangeN/A
Market Cap74.99M
Analysts82
Price Target0.27 (107.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.08%
Min Revenue beat(2)-13.84%
Max Revenue beat(2)-4.31%
Revenue beat(4)1
Avg Revenue beat(4)-5.66%
Min Revenue beat(4)-13.84%
Max Revenue beat(4)0.44%
Revenue beat(8)2
Avg Revenue beat(8)-3.13%
Revenue beat(12)4
Avg Revenue beat(12)-1.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.68%
PT rev (3m)6.68%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-50.02%
EPS NY rev (3m)-50.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.57%
Revenue NY rev (1m)4.85%
Revenue NY rev (3m)-4.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.25 | ||
| P/S | 0.81 | ||
| P/FCF | 55.22 | ||
| P/OCF | 31.72 | ||
| P/B | 1.19 | ||
| P/tB | 1.21 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY23.54%
FCF(TTM)0
FCFY1.81%
OCF(TTM)0
OCFY3.15%
SpS0.16
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.45% | ||
| ROE | 17.3% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 11.74% | ||
| GM | 28.07% | ||
| FCFM | 1.46% |
ROA(3y)0.61%
ROA(5y)-1.43%
ROE(3y)0.45%
ROE(5y)-4.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y45.46%
PM growth 5YN/A
GM growth 3Y72.19%
GM growth 5Y-2.05%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | 34.7 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 18.51% | ||
| Cap/Sales | 1.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 12.46% | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 0.43 | ||
| Altman-Z | 1.06 |
F-Score5
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)70.46%
Cap/Depr(5y)95.47%
Cap/Sales(3y)2.65%
Cap/Sales(5y)5.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70%
EPS 3Y90.7%
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y235.97%
EPS Next 2Y124.94%
EPS Next 3Y77.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.89%
Revenue growth 3Y20.83%
Revenue growth 5Y71.51%
Sales Q2Q%34.67%
Revenue Next Year28.61%
Revenue Next 2Y24.25%
Revenue Next 3Y20.73%
Revenue Next 5Y12.81%
EBIT growth 1Y-316.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year315.52%
EBIT Next 3Y73.13%
EBIT Next 5Y47.89%
FCF growth 1Y-70.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.85%
OCF growth 3YN/A
OCF growth 5YN/A